Dose–response relationships of psilocybin-induced subjective experiences in humans
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Background: Psilocybin is the psychoactive component in Psilocybe mushrooms (‘magic mushrooms’). Whether and how the quality of the psilocybin-induced experience might mediate beneficial health outcomes is currently under investigation, for example, in therapeutic applications. However, to date, no meta-analysis has investigated the dose-dependency of subjective experiences across available studies. Aim: Establishing dose–response relationships of the subjective experiences induced by psilocybin in healthy study participants and a comparison of patient groups. Method: We applied a linear meta-regression approach, based on the robust variance estimation framework, to obtain linear dose–response relationship estimates on questionnaire ratings after oral psilocybin administration. Data were obtained from the Altered States Database, which contains data extracted from MEDLINE-listed journal articles that used standardized and validated questionnaires: the Altered States of Consciousness Rating Scale, the Mystical Experience Questionnaire and the Hallucinogen Rating Scale. Results: Psilocybin dose positively correlated with ratings on most factors and scales, mainly those referring to perceptual alterations and positively experienced ego dissolution. Measures referring to challenging experiences exhibited small effects and were barely modulated by dose. Conclusion: Psilocybin intensified almost all characteristics of altered states of consciousness assessed with the given questionnaires. Because subjective experiences are not only determined by dose, but also by individual and environmental factors, the results may only apply to controlled laboratory experiments and not to recreational use. This paper may serve as a general literature citation for the use of psilocybin in experimental and clinical research, to compare expected and observed subjective experiences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A basic introduction to fixed-effect and random-effects models for meta-analysis
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.12 · Cited by 6,793
The varieties of religious experience: A study in human nature.
James, W. (1902) · doi:10.1037/10004-000 · Cited by 5,204
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 9×
“…2015), the sensitivity analyses produced robust effect size estimates for different values of p. Additional meta-analysis including patient data In the additional analysis, we included the available patient data on the 5D-ASC (Bogenschutz et al., 2015; Griffiths et al., 2016; Grob et al., 2011;)”
BackgroundMethodResultInfluentialRobust variance estimation in meta‐regression with dependent effect size estimates
Hedges, L. V., Tipton, E., & Johnson, M. C. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.5 · Cited by 2,086 · cited 3×
“A recently presented meta-analytical approach, the robust variance estimation (RVE) framework (Hedges et al., 2010; Tipton, 2015), permits the inclusion of small samples and statistically dependent effect sizes to determine reliable dose–response estimates.”
MethodBasics of meta‐analysis: I 2 is not an absolute measure of heterogeneity
Borenstein, M., Higgins, J. P. T., Hedges, L. V., & Rothstein, H. R. (2017) · Research Synthesis Methods · doi:10.1002/jrsm.1230 · Cited by 1,848 · cited 4×
“…across studies, I², represents the proportion of the observed variance that is due to systematic differences between studies rather than random error, for example, resulting from differences in study population, study design or bias (Borenstein et al., 2017; Higgins and Thompson, 2002).”
MethodResultInfluentialAnalysing Data and Undertaking Meta‐Analyses
Deeks, J. J., Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch9 · Cited by 1,800
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 4×
“…reporting data on patients with cancer-related psychiatric distress (Ross et al., 2016), one study reporting data on patients with major depressive disorder (Davis et al., 2020) and two studies reporting data on patients with treatment-resistant major depression (Carhart-Harris et al., 2016, 2018).”
BackgroundResultInfluentialEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 6×
“…2015), the sensitivity analyses produced robust effect size estimates for different values of p. Additional meta-analysis including patient data In the additional analysis, we included the available patient data on the 5D-ASC (Bogenschutz et al., 2015; Griffiths et al., 2016; Grob et al., 2011;)”
MethodResultInfluentialHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 2×
“After ingestion, psilocybin is rapidly dephosphorylated to psilocin (4-hydroxy-N,Ndimethyltryptamine), which is mainly responsible for the psychedelic effects via partial agonist action at serotonin type 2A (5-HT2A) receptors (Vollenweider et al., 1998), similar to other classic psychedelics (Nichols, 2016).”
BackgroundPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · cited 9×
“…reporting data on patients with cancer-related psychiatric distress (Ross et al., 2016), one study reporting data on patients with major depressive disorder (Davis et al., 2020) and two studies reporting data on patients with treatment-resistant major depression (Carhart-Harris et al., 2016, 2018).”
BackgroundMethodResultInfluentialPsilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 1×
“…2011), and therapeutic outcomes in patients with alcohol use disorder (Bogenschutz et al., 2015), nicotine use disorder (Garcia-Romeu et al., 2015; Johnson et al., 2014, 2017), major depression (Carhart-Harris et al., 2016, 2018; Davis et al., 2020; Roseman et al., 2018) and cancer-related…”
BackgroundGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Small sample adjustments for robust variance estimation with meta-regression.
Tipton, E. (2015) · Psychological Methods · doi:10.1037/met0000011 · Cited by 810 · cited 5×
“Therefore, in line with (Tipton, 2015), the sensitivity analyses produced robust effect size estimates for different values of p.”
MethodResultInfluentialRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 3×
“Previous work also suggests a linear relationship of subjective experiences for medium to high doses of psilocybin is a good fitting model (Vollenweider and Kometer, 2010; Studerus et al., 2011).”
BackgroundMethodLong-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · cited 3×
“The second way of analysis uses only 42 items of the three core dimensions (Studerus et al., 2010) and summarizes the item scores along 11 factors (11-ASC)., These factors can be correspondingly considered subscales of the three core dimensions and have been termed (1) Experience of Unity, (2)…”
MethodInfluentialA solution to minimum sample size for regressions
Jenkins, D. G., & Quintana-Ascencio, P. F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0229345 · Cited by 665 · cited 1×
“Jenkins and Quintana-Ascencio (2020) suggest that eight studies is the minimum amount for meta-regressions to be informative when the variance is small and 25 when variance is large.”
BackgroundValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Tanner-Smith, E. E., & Tipton, E. (2014) · Research Synthesis Methods · doi:10.1002/jrsm.1091 · Cited by 588
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 6×
“Since classic psychedelics like psilocybin are usually characterized by a lack of sedation and clouding of consciousness, it was suggested that the effect of psilocybin on Vigilance Reduction rather reflects the state of contemplativeness, dreaminess and a reduction in attentiveness (Studerus et al., 2011).”
BackgroundInfluentialGriffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Constructing drug effects: a history of set and setting
Hartogsohn, I. (2017) · Drug Science Policy and Law · doi:10.1177/2050324516683325 · Cited by 472 · cited 2×
“…by dose, but also by non-pharmacological factors like the psychological state of the individual and the setting of psilocybin administration (Hartogsohn, 2017; Leary et al., 1963; Zinberg, 1984), it is worth comparing dose–responses across studies to elucidate the variability of subjective…”
BackgroundStrassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Are there levels of consciousness?
Bayne, T., Hohwy, J., & Owen, A. M. (2016) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2016.03.009 · Cited by 438 · cited 1×
“To allow comparability with previous reports, we used spiderplots for the visualization of the results for all questionnaires, inspired by the reports of Vollenweider and Kometer (2010) and Bayne et al. (2016).”
MethodPredicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W., & Griffiths, R. R. (2012) · Journal for the Scientific Study of Religion · doi:10.1111/j.1468-5906.2012.01685.x · Cited by 405
Handling Complex Meta-analytic Data Structures Using Robust Variance Estimates: a Tutorial in R
Tanner-Smith, E. E., Tipton, E., & Polanin, J. R. (2016) · Journal of Developmental and Life-Course Criminology · doi:10.1007/s40865-016-0026-5 · Cited by 390
Prediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369
Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897615 · Cited by 360
Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim
Hofmann, A., Heim, R., Brack, A., & Kobel, H. (1958) · Experientia · doi:10.1007/bf02159243 · Cited by 282
robumeta: An R-package for robust variance estimation in meta-analysis
Fisher, Z., & Tipton, E. (2015) · arXiv · doi:10.48550/arxiv.1503.02220 · Cited by 280 · cited 2×
“Analyses were performed using the robumeta package (Fisher and Tipton, 2015) in R version 3.”
MethodInfluentialPsilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276
Smigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.04.009 · Cited by 248 · cited 6×
“…to the experience (Studerus et al., 2012) have been associated with challenging experiences, whereas feeling well prepared, having a recreational intention and emotional reappraisal have been shown to reduce the occurrence of challenging experiences (Haijen et al., 2018; Smigielski et al., 2019a).”
BackgroundResultInfluentialModern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236 · cited 1×
“So far, no dose–response relationships have been established for those substances, but a report by Liechti (2017) analysed data on LSD from three studies performed by their research group, which showed a comparable pattern of response on the 11-ASC and MEQ30.”
BackgroundThe experimental use of psychedelic (LSD) psychotherapy.
Pahnke, W. N. (1970) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1970.03170240060010 · Cited by 220
Effect of Psilocybin on Empathy and Moral Decision-Making
Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx047 · Cited by 197 · cited 1×
“However, the only study in our analysis (11-ASC) using magnetic resonance imaging (Pokorny et al., 2017) reported similar effects compared with the other studies on scales referring to challenging experiences: Anxiety and Impaired Control and Cognition.”
ResultPharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Brown, R. T., Nicholas, C. R., Cozzi, N. V., Gassman, M. C., Cooper, K. M., Muller, D., Thomas, C. D., Hetzel, S. J., Henriquez, K. M., Ribaudo, A. S., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0540-6 · Cited by 188 · cited 1×
“Further, differences in individual pharmacokinetics were reported in terms of plasma psilocin levels and 5-HT2AR occupancy, which were found to correlate with the overall subjective experience (Brown et al., 2017; Hasler et al., 2004; Lindenblatt et al., 1998; Madsen et al., 2020).”
BackgroundMadsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.02.001 · Cited by 183 · cited 3×
“The quality of the experience seems to be associated with positive changes in mood, attitude and behaviour in healthy individuals (Griffiths et al., 2006, 2008, 2011, 2018; MacLean et al., 2011; Madsen et al., 2020; Studerus et al., 2011), and therapeutic outcomes in patients with alcohol use disorder (Bogenschutz et…”
BackgroundSmigielski, L., Kometer, M., Scheidegger, M., Krähenmann, R., Huber, T., & Vollenweider, F. X. (2019) · Scientific Reports · doi:10.1038/s41598-019-50612-3 · Cited by 176 · cited 6×
“…to the experience (Studerus et al., 2012) have been associated with challenging experiences, whereas feeling well prepared, having a recreational intention and emotional reappraisal have been shown to reduce the occurrence of challenging experiences (Haijen et al., 2018; Smigielski et al., 2019a).”
BackgroundResultInfluentialEffects of serotonin 2A/1A receptor stimulation on social exclusion processing
Preller, K. H., Pokorny, T., Hock, A., Kraehenmann, R., Stämpfli, P., Seifritz, E., Scheidegger, M., & Vollenweider, F. X. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524187113 · Cited by 169 · cited 1×
“We therefore included the data on the larger samples and excluded the data from Carter et al. (2007) and Preller et al. (2016).”
MethodPsilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans
Carter, O. L., Hasler, F., Pettigrew, J. D., Wallis, G. M., Liu, G. B., & Vollenweider, F. X. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0930-9 · Cited by 146
Risk of bias: a simulation study of power to detect study-level moderator effects in meta-analysis
Hempel, S., Miles, J. N., Booth, M. J., Wang, Z., Morton, S. C., & Shekelle, P. G. (2013) · Systematic Reviews · doi:10.1186/2046-4053-2-107 · Cited by 137 · cited 1×
“Hempel et al. (2013) consider heterogeneity to be the most important factor in assessing power in meta-analyses.”
BackgroundCarbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4769-4 · Cited by 133
Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments
Schmidt, A., Bachmann, R., Kometer, M., Csomor, P. A., Stephan, K. E., Seifritz, E., & Vollenweider, F. X. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.261 · Cited by 121 · cited 1×
“Two articles, Wittmann et al. (2007) and Schmidt et al. (2012), reported the identical data as they were previously reported in another article and were therefore excluded from the analysis.”
ResultCarter, O. L., Pettigrew, J. D., Hasler, F., Wallis, G. M., Liu, G. B., Hell, D., & Vollenweider, F. X. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300621 · Cited by 118
Uthaug, M. V., Lancelotta, R., Szabo, A., Davis, A. K., Riba, J., & Ramaekers, J. G. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05414-w · Cited by 117 · cited 2×
“Similarly, studies with DMT and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) report a largely comparable pattern of responses on both versions of the ASC rating scale (Uthaug et al., 2020), MEQ30 (Barsuglia et al.”
Resultdos Santos, R. G., & Hallak, J. E. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.001 · Cited by 111
Neuroticism is associated with challenging experiences with psilocybin mushrooms
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017) · Personality and Individual Differences · doi:10.1016/j.paid.2017.06.004 · Cited by 98 · cited 1×
“The trait neuroticism has been reported to increase the occurrence of challenging experiences in some studies (Barrett et al., 2017; Dittrich, 1994; Hemsley and Ward, 1985), while other studies did not find such an association (Haijen et al., 2018; Smigielski et al., 2019a; Studerus et al., 2012).”
Result
Cited by
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., O’Keane, V., Peck, S. K., Simmons, H., Sisa, C., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01648-7 · Cited by 187
“The 5D-ASC outcome in the present study is also consistent with a meta-analysis of studies of psilocybin in healthy volunteers and COMP 001 where participants with TRD were withdrawn from antidepressant drugs [5, 49].”
BackgroundResultPerez, N., Langlest, F., Mallet, L., De Pieri, M., Sentissi, O., Thorens, G., Seragnoli, F., Zullino, D., Kirschner, M., Kaiser, S., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.07.011 · Cited by 88
“…of anxiety ( Carhart-Harris et al., 2016 ), and the very nature of psychedelics trips with dose-dependent effect for ego dissolution that can be associated with a sense of loss of control with subsequent levels of anxiety or even short-term psychosis-like symptoms ( Hirschfeld and Schmidt, 2021 ).”
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“A precise mechanistic understanding of psychedelics is challenging because of the synergistic action of pharmacotherapy and psychotherapy, together with the induction of a wide range of complex subjective experiences with marked individual variation (19).”
BackgroundEvens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231172254 · Cited by 56
Systematic review of psychometric instruments used in research with psychedelics
de Deus Pontual, A. A., Senhorini, H. G., Corradi-Webster, C. M., Tófoli, L. F., & Daldegan-Bueno, D. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2079108 · Cited by 36
Metadata
- Authors
- Hirschfeld, T., & Schmidt, T. T.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-03-04
- Volume
- 35
- Issue
- 4
- Pages
- 384-397
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3135335789
- Cited by
- 93
- References
- 62
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.